|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Advanced Prostate Cancer Treatment Cost Analysis and Patient Impact in the VA Healthcare System |
| Daniel Lee, MD, MS |
| Daniel Lee discusses patient-facing costs for advanced prostate cancer treatment within the VA Health Care System. The conversation explores how recent legislation and VA programs, including the Cleland-Dole Act of 2022, have improved access to care through initiatives like the National Tele-Oncology Program and Precision Oncology Program. |
|
|
|
|
|
|
|
|
|
|
|
| VA's Million Veterans Program Reveals Crucial Genetic Data for Prostate Cancer Treatment |
Bruce Montgomery, MD
Bruce Montgomery discusses the pivotal role of germline testing in cancer predisposition, particularly within the Million Veterans Program. Focusing on prostate cancer, Dr. Montgomery explains that germline testing, which examines inherited DNA, can identify individuals with genetic predispositions to various cancers, including prostate, breast, ovarian, and pancreatic. |
|
|
|
|
|
|
|
|
|
|
| Mental Health and Prostate Cancer in the Veterans Population |
Zachary Klaassen, MD, MSc
Alicia Morgans speaks with Zach Klaassen about his research focusing on the intersection of mental health and prostate cancer care in the veterans’ population. Dr. Klaassen shares insights from his extensive study aimed at creating the world's largest prostate cancer mental health database. |
|
|
|
|
|
|
|
|
|
|
| Should Veterans be Classified as High Risk for Prostate Cancer Screening: A Review of the Current Literature |
| Gal Saffati, MD |
| Gal Saffati presents a systematic review evaluating whether veterans should be considered a high-risk group for prostate cancer screening. Findings showed that veterans have higher prostate cancer rates, with specific exposures, such as Agent Orange and aromatic hydrocarbons, linked to increased risk. The review suggests that veterans may benefit from enhanced screening guidelines, though further research is needed to solidify these associations. |
|
|
|
|
|
| Oncogenic Alteration Rates, Race, and Prostate Cancer Specific Mortality in Veterans with Metastatic Prostate Cancer Undergoing Somatic Tumor next Generation Sequencing |
| Luca Faustino Valle, MD |
| Luca Faustino Valle presents a study examining oncogenic alteration rates, race, and prostate cancer-specific mortality in veterans with metastatic prostate cancer undergoing next-generation sequencing. The study found that while non-Hispanic Black veterans had distinct patterns of genetic alterations compared to non-Hispanic White veterans, such as higher rates of SPOP and BRAF alterations, race was not independently linked to mortality after adjustments. |
|
|
|
|
|
|
|
|
|
|
| Remote Delivery of Cancer Genetic Testing in Veterans with Metastatic Prostate Cancer: A Million Veteran Program Study
|
| Robert Montgomery, MD
|
| Robert Montgomery presents a study on the remote delivery of germline genetic testing in veterans with metastatic prostate cancer, conducted through the Veteran’s Administration Million Veteran Program. The study, aimed at overcoming barriers to in-person genetic testing, found that 23% of eligible veterans completed testing through remote consenting and saliva collection, yielding a significantly higher uptake than typical community rates.
|
|
|
|
|
|
| Veterans Affairs Seamless Phase II/III Randomized Trial of Standard Systemic Therapy with or Without PET-Directed Local Therapy for Oligometastatic Prostate Cancer (VA STARPORT) |
| Abhishek A. Solanki, MD, MS |
| Abhishek Solanki presented the VA STARPORT trial, a phase II/III Veterans Affairs study examining the impact of adding PET-directed local therapy to standard systemic therapy for oligometastatic prostate cancer. The primary endpoint is castrate-resistant-free survival, and secondary endpoints focus on further oncologic and translational outcomes. This trial aims to assess whether PET-directed local therapy can enhance disease control in this veteran population. |
|
|
|
|
|
| Hospitalizations Among Veterans Treated for Metastatic Prostate Cancer with Abiraterone or Enzalutamide - Beyond the Abstract
|
| Martin Schoen, MD, MPH
|
| In this study, Riekhof et al. analyzed hospitalization rates among U.S. veterans with metastatic prostate cancer treated with abiraterone or enzalutamide, revealing a 22% increase in hospitalizations with abiraterone compared to a 3% rise with enzalutamide. Abiraterone-treated patients showed higher rates of hospitalizations for cardiovascular issues and infections such as UTIs, pneumonia, and sepsis, likely influenced by the immune-suppressive effects of prednisone used with abiraterone.
|
|
|
|
|
|
|
|
|
|
|
